HIMS & HERS HEALTH STOCK RISES 1% AFTER NEARLY 65% INCREASE OVER LAST THREE SESSIONS
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 17 hours ago
0mins
Should l Buy HIMS?
Source: moomoo
Health Share Increase: HIMS & HERS reported a 1% increase in health shares following a significant surge in past sessions.
Surge in Sessions: The company experienced nearly a 65% surge in sessions over the last three sessions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HIMS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HIMS
Wall Street analysts forecast HIMS stock price to rise
12 Analyst Rating
3 Buy
6 Hold
3 Sell
Hold
Current: 25.880
Low
16.50
Averages
32.95
High
60.00
Current: 25.880
Low
16.50
Averages
32.95
High
60.00
About HIMS
Hims & Hers Health, Inc. provides a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of chronic conditions, including those related to sexual health, hair loss, dermatology, mental health, and weight loss. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies on a subscription basis. It also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products. Through its mobile applications, consumers can access a range of educational programs, wellness content, and other services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Hims Stock Soars 50% Following Novo Partnership and Legal Settlement
- Stock Surge: Hims & Hers Health Inc. shares have surged nearly 50% since Monday, marking its best week ever, primarily driven by the partnership with Novo Nordisk to offer Ozempic and Wegovy, indicating a strong market rebound for the company.
- Legal Resolution: Novo Nordisk's withdrawal of its patent infringement lawsuit against Hims removes a significant legal overhang, allowing Hims to continue selling compounded GLP-1 drugs, which is expected to further boost sales and enhance market confidence.
- Executive Appointment: Hims has appointed former Eli Lilly communications executive Kathryn Beiser as Chief Communications Officer, responsible for overseeing internal and external communications, reflecting the company's strategic focus on expanding its healthcare platform and enhancing brand image.
- Investor Sentiment Shift: Following the partnership announcement with Novo, investor sentiment has turned extremely bullish, with message volumes on Stocktwits surging over 400%, indicating strong market confidence in Hims' future prospects.
See More
Hims & Hers Health Shares Drop 7.75% Amid Profit-Taking
- Stock Fluctuation: Hims & Hers Health closed at $23.84 on Thursday, down 7.88%, primarily due to traders taking profits after a strong rally following its partnership with Novo Nordisk, indicating market concerns over the execution of its branded obesity drugs.
- Surge in Trading Volume: The trading volume reached 68 million shares, about 126% above the three-month average of 30 million shares, reflecting heightened market interest in the company's dynamics, and despite the price drop, investors remain focused on its future performance.
- Long-Term Performance Analysis: Despite Thursday's decline, Hims & Hers saw a 50% increase in stock price over the last five trading days, driven by the Novo Nordisk partnership, impressive earnings report, and analyst upgrades, showcasing a strong short-term rebound.
- Legal Risk Warning: Investors should be aware of the legal risks associated with the company's products potentially falling into a gray area around patent protections, particularly as they monitor potential litigation and partnership agreements that could impact the company's long-term growth prospects.
See More
Midday Stock Highlights: Notable Movements in Multiple Stocks
- Market Decline: Mercado Libre's shares fell over 6% after JPMorgan downgraded its rating from overweight to neutral, citing increased competition and prolonged margin pressures, with the price target cut from $2,650 to $2,100, indicating concerns about future profitability.
- Cruise Industry Pressure: Shares of Royal Caribbean and Carnival dropped 5% and 6%, respectively, as oil prices surged past $100 per barrel, with fuel being one of the largest operating expenses for cruise operators, potentially impacting their profitability.
- Energy Stocks Rise: Constellation Energy and Vistra saw their shares increase by 2% following the Department of Energy's announcement of a plan to leverage existing nuclear energy infrastructure for increased power generation, highlighting the strategic importance of nuclear energy for future growth.
- Pet Health Surge: Petco Health and Wellness shares surged nearly 30% after the company indicated a potential return to sales growth, guiding for full-year revenue growth between flat and 1.5%, exceeding market expectations and reflecting confidence in its business recovery.
See More
Novo Nordisk Partners with Hims & Hers to Boost Sales
- Market Competition Pressure: Novo Nordisk is losing market share to Eli Lilly in the weight-loss drug sector, which has negatively impacted its sales, although its GLP-1 products still hold significant market potential.
- Strategic Partnership Agreement: The agreement with Hims & Hers allows Novo Nordisk to sell FDA-approved drugs at the same self-pay prices on the platform, which is expected to reduce the appeal of non-FDA-approved versions and boost sales volume.
- Patent Lawsuit Shift: By partnering with Hims & Hers, Novo Nordisk avoids potentially high patent litigation costs while redirecting demand towards its branded medications, thereby enhancing its competitive position in the market.
- Future Product Outlook: Despite a projected revenue decline this year, Novo Nordisk's next-gen GLP-1 drug CagriSema is expected to gain approval within 10 months, with a promising pipeline that could lead to revenue growth over the next three years.
See More
Hims & Hers Partners with Novo Nordisk, Boosting Stock Sentiment
- Partnership Formation: Hims & Hers has established a new partnership with Novo Nordisk to introduce branded GLP-1 treatments like Ozempic and Wegovy, which alleviates legal concerns and strengthens collaboration with a major pharmaceutical company, likely boosting market confidence.
- Weight Loss Strategy Shift: The company is transitioning its U.S. weight-loss business towards FDA-approved treatments, ceasing active promotion of compounded GLP-1 drugs, allowing existing patients to switch to branded therapies when clinically appropriate, aiming to enhance treatment efficacy and patient satisfaction.
- Short Interest Pressure: Short interest in Hims has risen from 81.01 million to 84.96 million shares, with 46.09% of the public float currently held short; given the average daily volume of 32.93 million shares, it would take 2.58 days for short sellers to cover their positions, indicating market attention on potential price rebounds.
- Technical Analysis Status: Hims is trading 59.9% above its 20-day simple moving average but 16% below its 100-day moving average, indicating a strong short-term bounce that has yet to repair the longer-term trend, with shares down 23.73% over the past 12 months.
See More
HIMS & HERS HEALTH STOCK RISES 1% AFTER NEARLY 65% INCREASE OVER LAST THREE SESSIONS
Health Share Increase: HIMS & HERS reported a 1% increase in health shares following a significant surge in past sessions.
Surge in Sessions: The company experienced nearly a 65% surge in sessions over the last three sessions.
See More
Hims Stock Soars 50% Following Novo Partnership and Legal Settlement
- Stock Surge: Hims & Hers Health Inc. shares have surged nearly 50% since Monday, marking its best week ever, primarily driven by the partnership with Novo Nordisk to offer Ozempic and Wegovy, indicating a strong market rebound for the company.
- Legal Resolution: Novo Nordisk's withdrawal of its patent infringement lawsuit against Hims removes a significant legal overhang, allowing Hims to continue selling compounded GLP-1 drugs, which is expected to further boost sales and enhance market confidence.
- Executive Appointment: Hims has appointed former Eli Lilly communications executive Kathryn Beiser as Chief Communications Officer, responsible for overseeing internal and external communications, reflecting the company's strategic focus on expanding its healthcare platform and enhancing brand image.
- Investor Sentiment Shift: Following the partnership announcement with Novo, investor sentiment has turned extremely bullish, with message volumes on Stocktwits surging over 400%, indicating strong market confidence in Hims' future prospects.
See More
Hims & Hers Health Shares Drop 7.75% Amid Profit-Taking
- Stock Fluctuation: Hims & Hers Health closed at $23.84 on Thursday, down 7.88%, primarily due to traders taking profits after a strong rally following its partnership with Novo Nordisk, indicating market concerns over the execution of its branded obesity drugs.
- Surge in Trading Volume: The trading volume reached 68 million shares, about 126% above the three-month average of 30 million shares, reflecting heightened market interest in the company's dynamics, and despite the price drop, investors remain focused on its future performance.
- Long-Term Performance Analysis: Despite Thursday's decline, Hims & Hers saw a 50% increase in stock price over the last five trading days, driven by the Novo Nordisk partnership, impressive earnings report, and analyst upgrades, showcasing a strong short-term rebound.
- Legal Risk Warning: Investors should be aware of the legal risks associated with the company's products potentially falling into a gray area around patent protections, particularly as they monitor potential litigation and partnership agreements that could impact the company's long-term growth prospects.
See More
Midday Stock Highlights: Notable Movements in Multiple Stocks
- Market Decline: Mercado Libre's shares fell over 6% after JPMorgan downgraded its rating from overweight to neutral, citing increased competition and prolonged margin pressures, with the price target cut from $2,650 to $2,100, indicating concerns about future profitability.
- Cruise Industry Pressure: Shares of Royal Caribbean and Carnival dropped 5% and 6%, respectively, as oil prices surged past $100 per barrel, with fuel being one of the largest operating expenses for cruise operators, potentially impacting their profitability.
- Energy Stocks Rise: Constellation Energy and Vistra saw their shares increase by 2% following the Department of Energy's announcement of a plan to leverage existing nuclear energy infrastructure for increased power generation, highlighting the strategic importance of nuclear energy for future growth.
- Pet Health Surge: Petco Health and Wellness shares surged nearly 30% after the company indicated a potential return to sales growth, guiding for full-year revenue growth between flat and 1.5%, exceeding market expectations and reflecting confidence in its business recovery.
See More
Novo Nordisk Partners with Hims & Hers to Boost Sales
- Market Competition Pressure: Novo Nordisk is losing market share to Eli Lilly in the weight-loss drug sector, which has negatively impacted its sales, although its GLP-1 products still hold significant market potential.
- Strategic Partnership Agreement: The agreement with Hims & Hers allows Novo Nordisk to sell FDA-approved drugs at the same self-pay prices on the platform, which is expected to reduce the appeal of non-FDA-approved versions and boost sales volume.
- Patent Lawsuit Shift: By partnering with Hims & Hers, Novo Nordisk avoids potentially high patent litigation costs while redirecting demand towards its branded medications, thereby enhancing its competitive position in the market.
- Future Product Outlook: Despite a projected revenue decline this year, Novo Nordisk's next-gen GLP-1 drug CagriSema is expected to gain approval within 10 months, with a promising pipeline that could lead to revenue growth over the next three years.
See More
Hims & Hers Partners with Novo Nordisk, Boosting Stock Sentiment
- Partnership Formation: Hims & Hers has established a new partnership with Novo Nordisk to introduce branded GLP-1 treatments like Ozempic and Wegovy, which alleviates legal concerns and strengthens collaboration with a major pharmaceutical company, likely boosting market confidence.
- Weight Loss Strategy Shift: The company is transitioning its U.S. weight-loss business towards FDA-approved treatments, ceasing active promotion of compounded GLP-1 drugs, allowing existing patients to switch to branded therapies when clinically appropriate, aiming to enhance treatment efficacy and patient satisfaction.
- Short Interest Pressure: Short interest in Hims has risen from 81.01 million to 84.96 million shares, with 46.09% of the public float currently held short; given the average daily volume of 32.93 million shares, it would take 2.58 days for short sellers to cover their positions, indicating market attention on potential price rebounds.
- Technical Analysis Status: Hims is trading 59.9% above its 20-day simple moving average but 16% below its 100-day moving average, indicating a strong short-term bounce that has yet to repair the longer-term trend, with shares down 23.73% over the past 12 months.
See More
HIMS & HERS HEALTH STOCK RISES 1% AFTER NEARLY 65% INCREASE OVER LAST THREE SESSIONS
Health Share Increase: HIMS & HERS reported a 1% increase in health shares following a significant surge in past sessions.
Surge in Sessions: The company experienced nearly a 65% surge in sessions over the last three sessions.
See More
